M

Middle East Pharmaceutical Industries Company SJSC
SAU:4016

Watchlist Manager
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Watchlist
Price: 121.2 SAR 1.68% Market Closed
Market Cap: 2.4B SAR
Middle East Pharmaceutical Industries Company SJSC
/
Balance Sheet
/
Accrued Liabilities

Middle East Pharmaceutical Industries Company SJSC
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Middle East Pharmaceutical Industries Company SJSC
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
M
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Accrued Liabilities
ď·Ľ17m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC
SAU:2070
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
J
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Accrued Liabilities
ď·Ľ130m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Middle East Pharmaceutical Industries Company SJSC
Glance View

Market Cap
2.4B SAR
Industry
Pharmaceuticals

Middle East Pharmaceutical Industries Company SJSC is a SA-based company operating in Pharmaceuticals industry. The company is headquartered in Riyadh, Riyadh and currently employs 335 full-time employees. The company went IPO on 2024-02-27. Middle East Pharmaceutical Industries Company SJSC is a Saudi Arabia-based pharmaceutical company. The firm develops, manufactures, markets, and distributes a wide range of generic medicines and pharmaceuticals. The Company’s activity is the manufacture of disinfectants and sterilizers for medical devices and products, the manufacture of disinfectants and sterilizers for non-medical use, the manufacture of cosmetics, and the manufacture of pharmaceutical preparations for human use.

Intrinsic Value
78.33 SAR
Overvaluation 35%
Intrinsic Value
Price
M
What is Intrinsic Value?

See Also

What is Middle East Pharmaceutical Industries Company SJSC's Accrued Liabilities?
Accrued Liabilities
17m SAR

Based on the financial report for Dec 31, 2023, Middle East Pharmaceutical Industries Company SJSC's Accrued Liabilities amounts to 17m SAR.

What is Middle East Pharmaceutical Industries Company SJSC's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
19%

Over the last year, the Accrued Liabilities growth was 75%. The average annual Accrued Liabilities growth rates for Middle East Pharmaceutical Industries Company SJSC have been 19% over the past three years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 244,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.